CXCR4-targeted modular peptide carriers for efficient anti-VEGF siRNA delivery

International Journal of Pharmaceutics

Volumn 515, Issue 1-2, 2016, Pages 431-440

  Egorova, Anna ^a   Shubina, Anastasia ^a   Sokolov, Dmitriy ^a   Selkov, Sergey ^a   Baranov, Vladislav ^a   Kiselev, Anton ^a  

^a D O OTT RESEARCH INSTITUTE OF OBSTETRICS   (Russian Federation)

Author keywords

Cross linking peptides; CXCR4; Endothelium; Glioblastoma; siRNA; VEGF

Indexed keywords

AMINOCAPROIC ACID DERIVATIVE; CHEMOKINE RECEPTOR CXCR4; POLYACRYLAMIDE GEL; POLYCATION; RIBONUCLEASE; SMALL INTERFERING RNA; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN A; CXCR4 PROTEIN, HUMAN; DRUG CARRIER; LIGAND; PEPTIDE;

AMINO TERMINAL SEQUENCE; ARTICLE; CELL VIABILITY; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME DEGRADATION; GENE EXPRESSION; GENE SILENCING; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; HYDROLYSIS; MIGRATION INHIBITION; NONVIRAL GENE DELIVERY SYSTEM; PARTICLE SIZE; PHYSICAL CHEMISTRY; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN CROSS LINKING; RESAZURIN ASSAY; SURFACE CHARGE; ZETA POTENTIAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; GENE THERAPY; METABOLISM; PROCEDURES; RNA INTERFERENCE; TUMOR CELL LINE;

CELL LINE, TUMOR; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; GENETIC THERAPY; HUMANS; LIGANDS; PEPTIDES; RECEPTORS, CXCR4; RNA INTERFERENCE; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84993982782     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2016.10.049     Document Type: Article

References (42)

1. Ameres, S.L., Martinez, J., Schroeder, R., Molecular basis for target RNA recognition and cleavage by human RISC. Cell 130 (2007), 101–112, 10.1016/j.cell.2007.04.037.
2. Andre, F., Soria, J.C., Assi, H., Delaloge, S., Spielmann, M., Expression of chemokine receptors by cancer cells. Bull. Cancer 91:Suppl 4 (2004), S254–S256.
3. Beidler, J.L., Hilliard, P.R., Rill, R.L., Ultrasensitive staining of nucleic acids with silver. Anal. Biochem. 126 (1982), 374–380, 10.1016/0003-2697(82)90530-9.
4. Chen, S., Feng, J., Ma, L., Liu, Z., Yuan, W., RNA interference technology for anti-VEGF treatment. Expert Opin. Drug Deliv. 11 (2014), 1471–1480, 10.1517/17425247.2014.926886.
5. David, S., Pitard, B., Benoit, J.P., Passirani, C., Non-viral nanosystems for systemic siRNA delivery. Pharmacol. Res. 62 (2010), 100–114, 10.1016/j.phrs.2009.11.013.
6. De Fougerolles, A., Frank-Kamenetsky, M., Manoharan, M., Rajeev, K. G., Hadwiger, P., 2011. IRNA agents targeting VEGF. U.S. Patent No. 7,919,473. Washington, DC. U.S. Patent and Trademark Office.
7. Detwiller, K.Y., Fernando, N.T., Segal, N.H., Ryeom, S.W., D'Amore, P.A., Yoon, S.S., Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor a. Cancer Res. 65 (2005), 5881–5889, 10.1158/0008-5472.can-04-4078.
8. Edgell, C.J., McDonald, C.C., Graham, J.B., Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc. Natl. Acad. Sci. U. S. A. 80 (1983), 3734–3737, 10.1073/pnas.80.12.3734.
9. Egorova, A.A., Kiselev, A.V., Peptide modules for overcoming barriers of nucleic acids transport to cells. Curr. Top. Med. Chem. 16 (2016), 330–342, 10.2174/1568026615666150812120755.
10. Egorova, A., Kiselev, A., Hakli, M., Ruponen, M., Baranov, V., Urtti, A., Chemokine-derived peptides as carriers for gene delivery to CXCR4 expressing cells. J. Gene Med. 11 (2009), 772–781, 10.1002/jgm.1366.
11. Egorova, A., Bogacheva, M., Shubina, A., Baranov, V., Kiselev, A., Development of a receptor-targeted gene delivery system using CXCR4 ligand-conjugated cross-linking peptides. J. Gene Med. 16 (2014), 336–351, 10.1002/jgm.2811.
12. Elbashir, S.M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., Tuschl, T., Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001), 494–498, 10.1038/35078107.
13. Eliceiri, B.P., Cheresh, D.A., Adhesion events in angiogenesis. Curr. Opin. Cell Biol. 13 (2001), 563–568, 10.1016/S0955-0674(00)00252-0.
14. Ferrara, N., Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9:Suppl 1 (2004), 2–10, 10.1634/theoncologist.9-suppl_1-2.
15. Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., Mello, C.C., Potent and specific genetic interference by double-stranded RNA in caenorhabditis elegans. Nature 391 (1998), 806–811, 10.1038/35888.
16. Fujii, W.H.P., Driessen, N., Tamamura, H., Sullivan, S.M., Development of peptide-targeted lipoplexes to CXCR4-expressing rat glioma cells and rat proliferating endothelial cells. Mol. Ther. 16 (2008), 516–524, 10.1038/sj.mt.6300388.
17. Gary, D.J., Puri, N., Won, Y.Y., Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. J. Control. Release 121 (2007), 64–73, 10.1016/j.jconrel.2007.05.021.
18. Huth, S., Hoffmann, F., von Gersdorff, K., Laner, A., Reinhardt, D., Rosenecker, J., Rudolph, C., Interaction of polyamine gene vectors with RNA leads to the dissociation of plasmid DNA-Carrier complexes. J. Gene Med. 8 (2006), 1416–1424, 10.1002/jgm.975.
19. Jones, N.A., Hill, I.R.C., Stolnik, S., Bignotti, F., Davis, S.S., Garnett, M.C., Polymer chemical structure is a key determinant of physicochemical and colloidal properties of polymer-DNA complexes for gene delivery. Biochim. Biophys. Acta Gene Struct. Expr. 1517 (2000), 1–18, 10.1016/S0167-4781(00)00220-7.
20. Juarez, J., Bendall, L., Bradstock, K., Chemokines and their receptors as therapeutic targets: the role of the SDF-1/CXCR4 axis. Curr. Pharm. Des. 10 (2004), 1245–1259, 10.2174/1381612043452640.
21. Kim, K.J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H.S., Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362 (1993), 841–844, 10.1038/362841a0.
22. Kiselev, A., Egorova, A., Laukkanen, A., Baranov, V., Urtti, A., Characterization of reducible peptide oligomers as carriers for gene delivery. Int. J. Pharm. 441 (2013), 736–747, 10.1016/j.ijpharm.2012.10.020.
23. Mulkeen, A.L., Silva, T., Yoo, P.S., Schmitz, J.C., Uchio, E., Chu, E., Cha, C., Short interfering RNA-mediated gene silencing of vascular endothelial growth factor: effects on cellular proliferation in colon cancer cells. Arch. Surg. 141 (2006), 367–374, 10.1158/0008-5472 CAN-04-4078.
24. Murata, N., Takashima, Y., Toyoshima, K., Yamamoto, M., Okada, H., Anti-tumor effects of anti-VEGF siRNA encapsulated with PLGA microspheres in mice. J. Control. Release 126 (2008), 246–254, 10.1016/j.jconrel.2007.11.017.
25. Neufeld, G., Cohen, T., Gengrinovitch, S., Poltorak, Z., Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13 (1999), 9–22, 10.1210/Er.2003-0027.
26. Reinhart-King, C. a., Endothelial cell adhesion and migration. Methods Enzymol. 443 (2008), 45–64, 10.1016/S0076-6879(08)02003-X.
27. Ruponen, M., Ylä-Herttuala, S., Urtti, A., Interactions of polymeric and liposomal gene delivery systems with extracellular glycosaminoglycans: physicochemical and transfection studies. Biochim. Biophys. Acta Biomembr. 1415 (1999), 331–341, 10.1016/S0005-2736(98)00199-0.
28. Salcedo, R., Oppenheim, J.J., Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses. Microcirculation 10 (2003), 359–370, 10.1038/sj.mn.7800200.
29. Shubina, A.N., Egorova, A.A., Baranov, V.S., Kiselev, A.V., Recent advances in gene therapy of endometriosis. Recent Pat. DNA Gene Seq. 7 (2013), 169–178, 10.2174/18722156113079990021.
30. Singha, K., Namgung, R., Kim, W.J., Polymers in small-interfering RNA delivery. Nucleic Acid Ther. 21 (2011), 133–147, 10.1089/nat.2011.0293.
31. Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., John, M., Kesavan, V., Lavine, G., Pandey, R.K., Racie, T., Rajeev, K.G., Röhl, I., Toudjarska, I., Wang, G., Wuschko, S., Bumcrot, D., Koteliansky, V., Limmer, S., Manoharan, M., Vornlocher, H.-P., Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432 (2004), 173–178, 10.1038/nature03121.
32. Spagnou, S., Miller, A.D., Keller, M., Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry 43 (2004), 13348–13356, 10.1016/j.jconrel.2007.05.021.
33. Truttmann, M.C., Rhomberg, T.A., Dehio, C., Combined action of the type IV secretion effector proteins BepC and BepF promotes invasome formation of bartonella henselae on endothelial and epithelial cells. Cell. Microbiol. 13 (2011), 284–299, 10.1111/j.1462-5822.2010.01535.x.
34. Vega-Villa, K.R., Takemoto, J.K., Yanez, J.A., Remsberg, C.M., Forrest, M.L., Davies, N.M., Clinical toxicities of nanocarrier systems. Adv. Drug Deliv. Rev. 60 (2008), 929–938, 10.1016/j.addr.2007.11.007.
35. Wagner, L., Marschall, V., Karl, S., Cristofanon, S., Zobel, K., Deshayes, K., Vucic, D., Debatin, K.-M., Fulda, S., Smac mimetic sensitizes glioblastoma cells to temozolomide-induced apoptosis in a RIP1- and NF-κB-dependent manner. Oncogene 32 (2012), 988–997, 10.1038/onc.2012.108.
36. Wang, Y., Hazeldine, S.T., Li, J., Oupický, D., Development of functional poly(amido amine) CXCR4 antagonists with the ability to mobilize leukocytes and deliver nucleic acids. Adv. Healthc. Mater. 4 (2015), 729–738, 10.1002/adhm.201400608.
37. Wang, Y., Xie, Y., Oupicky, D., Potential of CXCR4/CXCL12 chemokine axis in cancer drug delivery. Curr. Pharmacol. Rep. 2 (2016), 1–10, 10.1007/s40495-015-0044-8.
38. Wolff, J.A., Ludtke, J.J., Acsadi, G., Williams, P., Jani, A., Long-term persistence of plasmid DNA and foreign gone expression in mouse muscle. Hum. Mol. Genet. 1 (1992), 363–369, 10.1093/hmg/1.6.363.
39. Xie, Y., Wehrkamp, C.J., Li, J., Wang, Y., Wang, Y., Mott, J.L., Oupický, D., Delivery of miR-200 c mimic with poly(amido amine) CXCR4 antagonists for combined inhibition of cholangiocarcinoma cell invasiveness. Mol. Pharm. 13 (2016), 1073–1080, 10.1021/acs.molpharmaceut.5b00894.
40. Xu, L., Anchordoquy, T., Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-Based therapeutics. J. Pharm. Sci. 100 (2011), 38–52, 10.1002/jps.22243.
41. Ye, W., The complexity of translating anti-angiogenesis therapy from basic science to the clinic. Dev. Cell 37 (2016), 114–125, 10.1016/j.devcel.2016.03.015.
42. Zintchenko, A., Philipp, A., Dehshahri, A., Wagner, E., Simple modifications of branched PEI lead to highly efficient siRNA carriers with low toxicity. Bioconjug. Chem. 19 (2008), 1448–1455, 10.1021/bc800065f.